Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H24ClN3O5 |
| Molecular Weight | 457.907 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@H](CC1=CC=CC=C1)NC(=O)C2=CC3=C(N2)C=CC(Cl)=C3)C(=O)N4C[C@H](O)[C@H](O)C4
InChI
InChIKey=GVDRRZOORHCTAN-MJUUVYJYSA-N
InChI=1S/C23H24ClN3O5/c24-15-6-7-16-14(9-15)10-18(25-16)22(31)26-17(8-13-4-2-1-3-5-13)21(30)23(32)27-11-19(28)20(29)12-27/h1-7,9-10,17,19-21,25,28-30H,8,11-12H2,(H,26,31)/t17-,19-,20+,21+/m0/s1
| Molecular Formula | C23H24ClN3O5 |
| Molecular Weight | 457.907 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ingliforib, aka CP-368296, is a glycogen phosphorylase inhibitor with antihyperglycemic and cardioprotective properties. It has been implicated for use in the treatment of diabetes and for myocardial ischemic protection. Ingliforib was in phase II clinical trials for diabetes, but these efforts have been discontinued.
Originator
Sources: http://adisinsight.springer.com/drugs/800013336 | https://www.ncbi.nlm.nih.gov/pubmed/14615278
Curator's Comment: # Pfizer
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P00489 Gene ID: 1.00008976E8 Gene Symbol: PYGM Target Organism: Oryctolagus cuniculus (Rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/14615278 |
|||
Target ID: P06737|||Q641R5 Gene ID: 5836.0 Gene Symbol: PYGL Target Organism: Homo sapiens (Human) |
52.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14615278
Male New Zealand White male rabbits were anesthetized with 30 mg/kg pentobarbital sodium and maintained in an anesthetized state with 16 mg/kg/hour by continuous infusion of pentobarbital sodium. Fluid-filled catheters were placed in the jugular vein for drug administration and in the carotid artery for blood pressure measurements and for blood gas analysis. The heart was exposed by left thoracotomy and a suture was placed around a prominent branch of the left coronary artery. When arterial pressure, HR, and RPP had stabilized, the rabbits received a 15-second bolus of either 15.4 mg.kg of ingliforib or vehicle control, followed by constant infusion of 23.1 mg/kg/hour ingliforib or vehicle control for a total of 3.5 hours. Sixty minutes after the start of infusion, regional ischemia was produced by tightening the coronary artery snare for 30 min. The snare was released, and the heart was reperfused for an additional 120 min. At the end of either the ischemic period or reperfusion period, each rabbit was euthanized with an intravenous overdose of pentobarbital sodium (100 mg/kg). The heart was quickly excised and prepared for measurement of GP activity and glycogen content, or mounted on a Langendorff apparatus and perfused with physiological saline at 38.5°C for subsequent determination of infarct size. Baseline HR, MAP, and RPP were similar between vehicle control and ingliforib-treated groups. Ingliforib did not affect MAP or RPP; a modest reduction in HR of the ingliforib group was observed during reperfusion. Infarct size was significantly reduced by 52% in vivo while the the %AAR/LV did not differ. At the end of the 30-min period of regional ischemia, GPa and total GP activity were reduced by 65% and 40%, respectively, in the ischemic myocardium, and 41% and 33%, respectively, in the nonischemic myocardium
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14615278
The heart of anesthetized Male New Zealand White rabbits was rapidly removed from the chest and mounted in a Langendorf apparatus with a snare around the prominent branch of the left coronary artery. The heart was maintained by noncirculating perfusion in a modified Krebs solution of 118.5 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 24.8 mM NaHCO3, 2.5 mM CaCl2, and 10 mM glucose at a constant pressure of 80 mmHg in a heated water-jacketed organ bath with a temperature of 38.5°C. Perfusate pH was maintained at 7.4 to 7.5 by bubbling with 95% O2-5% CO2. A latex balloon was used to maintain a systolic pressure of 80-120 mmHg (<10 mmHg diastolic pressure) in the left ventricle. After a 30 min equilibration period, a constant perfusion of ingilforib (0.1, 1, or 10 microM) was initiated and maintained for the duration of the experiment. After 30 minutes of drug perfusion, a regional ischemia was produced by tightening the snare around the branch of the coronary artery. At the end of the ischemic period, the snare was released, and the heart reperfused for an additional 120 min. Administration of ingliforib did not significantly affect HR, LVDP, or CF in the isolated hearts. Ingliforib elicited a concentration-dependent reduction in infarct size in the isolated rabbit hearts; maximum reduction (69%) achieved with 10 microM ingliforib.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:33 GMT 2025
by
admin
on
Mon Mar 31 18:05:33 GMT 2025
|
| Record UNII |
UII7156WLU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29711
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MM-41
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
186392-65-4
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
C75982
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
8134
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
DTXSID4047252
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
UII7156WLU
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
C483083
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
300000034184
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104888
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY | |||
|
6451325
Created by
admin on Mon Mar 31 18:05:33 GMT 2025 , Edited by admin on Mon Mar 31 18:05:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|